Source: Eur Respir J 2002; 19: 1058-1063
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Johnell O., Pauwels R., Lofdahl C-G., Laitinen L.A., Postma D.S., Pride N.B., Ohlsson S.V.. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler(R). Eur Respir J 2002; 19: 1058-1063

Member's Comments

No comment yet.

Related content which might interest you: Loss of bone mineral density in patients with chronic obstructive pulmonary disease Source: Annual Congress 2007 - Primary care management of COPD Year: 2007 Current status of research on osteoporosis in COPD: a systematic review Source: Eur Respir J 2009; 34: 209-218 Year: 2009 Bone turnover markers, bone mineral density and body composition in Tunisian patients with chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Management of chronic cough and obstructive diseases Year: 2021 To study the severity of lung hyperinflation and bone mineral density in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Bone mineral density changes in male patients with chronic obstructive pulmonary disease: clinical and biochemical variables in correlation with glucocorticoids use Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009 Relationship between annual change of bone mineral density, emphysema and pulmonary function in patients with COPD Source: International Congress 2015 – COPD: notable points Year: 2015 The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001 Clinical severity of chronic obstructive pulmonary disease is associated with bone mineral density Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Osteoporosis in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 22: 64S-75S Year: 2003 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Source: Eur Respir J 2003; 21: 260-266 Year: 2003 What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002 Study of bone mineral density, hemogram and their correlations in patients with chronic obstructive pulmonary disease Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 A comparison of bone mineral density in elderly patients with COPD and bronchial asthma Source: Annual Congress 2007 - COPD and comorbidity Year: 2007 Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004 Undertreatment of loss of bone mineral density in patients with COPD who were referred for pulmonary rehabilitation Source: Eur Respir J 2006; 28: Suppl. 50, 71s Year: 2006 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005